- Home
- IONS vs PHI Comparison
IONS vs PHI Comparison
Compare IONS & PHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- PHI
- Stock Information
- Founded
- IONS 1989
- PHI 1928
- Country
- IONS United States
- PHI Philippines
- Employees
- IONS N/A
- PHI N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- PHI Telecommunications Equipment
- Sector
- IONS Health Care
- PHI Telecommunications
- Exchange
- IONS Nasdaq
- PHI Nasdaq
- Market Cap
- IONS 4.6B
- PHI 4.8B
- IPO Year
- IONS 1991
- PHI 1953
- Fundamental
- Price
- IONS $32.26
- PHI $23.67
- Analyst Decision
- IONS Buy
- PHI
- Analyst Count
- IONS 18
- PHI 0
- Target Price
- IONS $57.41
- PHI N/A
- AVG Volume (30 Days)
- IONS 1.7M
- PHI 61.6K
- Earning Date
- IONS 04-30-2025
- PHI 05-20-2025
- Dividend Yield
- IONS N/A
- PHI 7.19%
- EPS Growth
- IONS N/A
- PHI 21.44
- EPS
- IONS N/A
- PHI 2.57
- Revenue
- IONS $717,253,000.00
- PHI $3,733,350,583.00
- Revenue This Year
- IONS N/A
- PHI $4.32
- Revenue Next Year
- IONS $27.39
- PHI $2.64
- P/E Ratio
- IONS N/A
- PHI $9.08
- Revenue Growth
- IONS N/A
- PHI 2.79
- 52 Week Low
- IONS $23.95
- PHI $20.29
- 52 Week High
- IONS $52.34
- PHI $29.05
- Technical
- Relative Strength Index (RSI)
- IONS 57.55
- PHI 55.78
- Support Level
- IONS $31.66
- PHI $23.11
- Resistance Level
- IONS $33.98
- PHI $23.84
- Average True Range (ATR)
- IONS 1.30
- PHI 0.53
- MACD
- IONS 0.41
- PHI 0.06
- Stochastic Oscillator
- IONS 68.84
- PHI 73.68
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About PHI PLDT Inc. Sponsored ADR
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.